Galectin-16 (LGALS16)

Galectin-16 (LGALS16) is a soluble beta-galactoside-binding lectin, structurally characterized by a canonical carbohydrate recognition domain (CRD) with a β-sandwich fold[1][2]. It is encoded by the LGALS16 gene on chromosome 19q13 and is primarily expressed in the human placenta, where it plays a key role in maintaining immune tolerance at the maternal–fetal interface, likely by inducing apoptosis in maternal T-cells to protect the fetus from immune attack[1][2][3].[4] Expression is upregulated during trophoblast differentiation and is required for successful syncytiotrophoblast development[1][3]. Although it is mostly studied in the context of placental biology, LGALS16 is also detected at lower levels in certain brain tissues and may have developmental or regulatory functions there[1]. Dysregulation is associated with pregnancy disorders such as preeclampsia, and altered expression has been reported in some cancers, diabetes, and brain diseases[1]. There are currently no drugs targeting galectin-16, and its roles as a therapeutic target remain unexplored; however, its molecular and immunological functions suggest its importance in placental health and immune regulation[1][2][3][4][5].

Other names

Galectin-16LGALS16beta-galactoside-binding lectinlectin galactoside-binding soluble 16LEG16